

[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI
[ Thu, May 23rd 2024
] - WOPRAI

[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
[ Wed, May 22nd 2024
] - WOPRAI
Joanne Wuensch Upgraded (TNDM) to Strong Buy and Increased Target to $57 on, May 22nd, 2024
Joanne Wuensch of Citigroup, Upgraded "Tandem Diabetes Care, Inc." (TNDM) to Strong Buy and Increased Target from $40 to $57 on, May 22nd, 2024.
Joanne has made no other calls on TNDM in the last 4 months.
There are 6 other peers that have a rating on TNDM. Out of the 6 peers that are also analyzing TNDM, 2 agree with Joanne's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jeff Johnson of "Baird" Maintained at Hold with Increased Target to $36 on, Friday, May 3rd, 2024
- Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024
These are the ratings of the 4 analyists that currently disagree with Joanne
- Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $55 on, Monday, May 6th, 2024
- Matt O'Brien of "Piper Sandler" Reiterated at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
- Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
- Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024
Contributing Sources